Corrigendum to ‘VP1-2021: Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer’
Titel:
Corrigendum to ‘VP1-2021: Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer’
Auteur:
Bachelot, T. Dalenc, F. Chabaud, S. Cottu, P. Allouache, D. Brain, E. Jacquin, J.-P. Grenier, J. Venat Bouvet, L. Brunt, M. Campone, M. Del Piano, F. Debled, M. Hardy Bessard, A.-C. Giacchetti, S. Bliss, J. Canon, J.-L. Lemonnier, J. Cameron, D. André, F.